PACB (PACB) Stock Price & Analysis
PACB (PACB) rose 3.85% to USD 1.35 as of September 8, 2026 at 04:21 UTC, according to Nexqual real-time market data.
PACB last closed at USD 1.35; the session ranged USD 1.29–1.35 on volume of 2,764,523 shares. Market capitalization is —, with a 52-week range of USD 1.07–2.73 (NMS). Source: Nexqual, September 8, 2026 at 04:21 UTC.
Key Statistics (as of September 8, 2026 at 04:21 UTC)
| Price | USD 1.35 |
|---|---|
| Change | ▲ 3.85% (up) |
| Previous Close | USD 1.35 |
| Open | USD 1.35 |
| Day Range | USD 1.29 – 1.35 |
| 52-Week Range | USD 1.07 – 2.73 |
| Volume | 2,764,523 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (PACB)
Nexqual's technical model rates PACB "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 04:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.59 (neutral) |
| vs SMA50 | Below (USD 1.4) |
| MACD | 0 (positive) |
From PACB's Latest SEC 10-K Filing (filed 2026-02-25)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 124.72 | ▼ 4.79% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.74 | ▼ 0.16% |
| EDIT | Editas Medicine, Inc. | USD 3.23 | ▲ 4.87% |
| CRSP | CRISPR Therapeutics AG | USD 55.79 | ▼ 1.99% |
| BEAM | Beam Therapeutics Inc. | USD 29.66 | ▲ 1.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:21 UTC. This page is informational and not investment advice.